Lutris updates
News & Announcements
Updates on our clinical programs, corporate milestones, and financing.
Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025
Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025
Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer
Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel Demonstrating Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at AACR Annual Meeting 2025
Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment of EGFRI-Induced Acneiform Rash in Patients with Metastatic Colorectal Cancer
Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors
Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash
Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer
Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting
Lutris Pharma to Present at the 16th Annual European Life Sciences CEO Forum in March
Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing
Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-RAF Inhibitors in MEK Inhibitor induced rash
Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer
Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., Ph.D., as Chairman of the Board of Directors
Lutris Pharma to Present at the Bio€quity Europe Conference
Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer
Lutris Pharma to Participate in Virtual Investor Conferences in January
Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-RAF inhibitors Including Lead Asset LUT014
Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients
Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 — a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions — in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy
Lutris Pharma Appoints Life Science Executive, Jack Weinstein, as Chairman of the Board of Directors
Israel's Lutris shares positive readout from early-stage trials of B-RAF inhibitor
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
Topical therapy can help safely reduce side effect of cancer treatment
Novel B-RAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors
Side effect of cancer treatment can be safely reduced with topical cream